Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma

The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models.IC: NCINIH Ref. No.: E-130-2011Advantages: Monoclonal antibodies create a level of specificity that can reduce deleterious side-effectsMultiple treatment strategies available including the killing of cancer cells with a toxic agent or by inhibiting cell signalingNon-invasive and potentially non-liver toxic alternative to current HCC treatment strategiesApplications: Therapeutic candidates against cancers that overexpress GPC3Antibodies for killing cancer cells by inhibiting GPC3-based cell signaling, thereby inhibiting tumor cell growthCARs, immunotoxins and ADCs for killing cancer cellsDiagnostics for detecting cancers associated with GPC3 overexpressionSpecific cancers include hepatocellular cancer (HCC), melanoma, thyroid cancer, lung squamous cell carcinoma, Wilms tumor, neuroblastoma, hepatoblastoma, and testicular germ-cell tumorsDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 20, 2017Provider Classifications: Publications: Patent Application: PCT/US2012/034186201280029201.31271700915188264.4Patent Authority: USUSForeign FiledChineseEPEPPatent Number: 9,394,3649,206,257Licensing Contacts: Lead Inventor: Inventor IC: NCIInventor Lab URL: https://ccr.c...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research